NDT Advance Access originally published online on November 1, 2005
Nephrology Dialysis Transplantation 2006 21(2):459-465; doi:10.1093/ndt/gfi213
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Original Articles: Dialysis and Transplantation
Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study
1 Nephrology Service, Hospital Universitario de Canarias, Santa Cruz de Tenerife, 2 Nephrology Service, Hospital Universitario Reina Sofía, Cordoba, 3 Nephrology Service, Hospital Gregorio Marañon, Madrid, 4 Nephrology Unit, Hospital Clinic I Provincial, Barcelona, 5 Nephrology Service, Hospital Universitario ‘Dr Negrín’, Las Palmas de Gran Canaria and 6 Nephrology Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Correspondence and offprint requests to: Víctor Lorenzo, Division of Nephrology, University Hospital of Canary Islands, 38320 Ofra. La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain. Email: viclorenzo{at}terra.es
Background. This study evaluated the proportion of patients who met National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines for mineral status, and assessed the cost of therapy for mineral management of patients under haemodialysis treatment in Spain.
Methods. Demographic and biochemical data were collected for 1312 patients undergoing standard three-times weekly maintenance haemodialysis at six Spanish centres during December 2003. Age, gender, diabetic nephropathy, haemodialysis duration, serum calcium, phosphorus, calcium–phosphorus product (Ca x P), and intact parathyroid hormone (iPTH) levels were monitored. Exploratory analyses of associations between demographic and biochemical parameters, were undertaken using bivariate and multivariate regression techniques.
Results. Mean age of patients was 62 years. 97% were Caucasian, 23% were diabetic. In total, 51% of patients received calcium binders, 21% sevelamer, 16% aluminium hydroxide, and 29% received no binders; 33% of patients received calcitriol. Prevalence of patients outside K/DOQI targets was: calcium 50%, phosphorus 46%; Ca x P 33%; iPTH 77%. Elevated phosphorus (>5.5 mg/dl) was independently associated with younger age [OR 0.972 (95% CI 0.963–0.980), P<0.001] and higher iPTH [OR 1.0005 (95% CI 1.0002–1.0008), P<0.001]. Elevated Ca x P (
55 mg2 x dl2) showed a similar relationship. High iPTH levels (>300 pmol/l) were associated with female gender [OR 1.574 (95% CI 1.213–2.041), P<0.001], high serum phosphorus [OR 1.230 (95% CI 1.130–1.338), P<0.001], and longer duration of dialysis [OR 1.003 (95% CI 1.001–1.005), P<0.01]. Poorly controlled serum phosphorus, Ca x P and iPTH were associated with more expensive therapy for mineral management.
Conclusions. One in three haemodialysis patients in Spain remains above the upper target range defined in current mineral metabolism guidelines. This abnormal profile is more common in younger patients and females and therapy is more expensive in younger patients.
Keywords: calcium; calcium–phosphorus product; haemodialysis; parathyroid hormone; phosphate; renal osteodystrophy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Sullivan, S. S. Sayre, J. B. Leon, R. Machekano, T. E. Love, D. Porter, M. Marbury, and A. R. Sehgal Effect of Food Additives on Hyperphosphatemia Among Patients With End-stage Renal Disease: A Randomized Controlled Trial JAMA, February 11, 2009; 301(6): 629 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. M. de Francisco and F. Carrera A New Paradigm for the Treatment of Secondary Hyperparathyroidism NDT Plus, January 1, 2008; 1(suppl_1): i24 - i28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L.M. de Francisco, C. Pinera, R. Palomar, and M. Arias Impact of Treatment with Calcimimetics on Hyperparathyroidism and Vascular Mineralization J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S281 - S285. [Abstract] [Full Text] [PDF]
|
|